Potential Non Small Cell Lung Cancer Combo Therapy Tops AJPB Week in Review


Top news of the week from The American Journal of Pharmacy Benefits.

5. Benefits of Medicaid Expansion Found to Outweigh Negatives

Study finds Medicaid expansion associated with increases in coverage, service use, quality of care, and spending. Read more.

4. Esketamine Nasal Spray Shows Promise Depression Relapse

Esketamine is a glutamate receptor modulator capable of restoring synaptic connections in the brains of patients with depression. Read more.

3. Lenalidomide Combo Shows Promise as Frontline Therapy for Follicular Lymphoma

Rituximab (Rituxan) and lenalidomide (Revlimid) showed similar efficacy to rituximab plus chemotherapy, according to findings presented at the 2018 ASCO Annual Meeting. Read more.

2. Medicare Part A Will Become Insolvent in 2026

Trustees for Medicare said that Medicare Part A, which covers hospital bills, will become insolvent in 2026, 3 years earlier than the projection last year in its annual report. Read more.

1. Combination Effective Treating Non Small Cell Lung Cancer

Pegilodecakin (AM0010) with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate in 41% in patients with advanced non—small cell lung cancer, according to findings presented at the 2018 ASCO Annual meeting. Read more.

Related Videos
BillionPhotos.com - stock.adobe.com
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Image credit: Fabio Balbi | stock.adobe.com
Image credit: Melita - stock.adobe.com
Video 6 - "Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma"
Emergency CPR on a Man who has Heart Attack , One Part of the Process Resuscitation (First Aid) - Image credit: Platoo Studio | stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.